KANSAS CITY, Mo.--(BUSINESS WIRE)--A retrospective follow-up analysis of an ongoing prospective study of relapsing-remitting multiple sclerosis (RRMS) patients (n=285) taking immunomodulatory therapies (IMTs), found that after six years more than half of the patients (41/79) taking COPAXONE® (glatiramer acetate injection) had remained on treatment continuously, whereas less than thirty percent of patients (55/206) taking one of the interferon beta (IFN-ß) class of drugs remained in the study (p< 0.0001). The study, which included patients receiving either COPAXONE®, Avonex® (IFN-ß-1a IM), Betaseron® (IFN-ß-1b SC), or Rebif® (IFN-ß-1a SC), was presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), in Madrid, Spain.
